{
    "Clinical Trial ID": "NCT01091168",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Vinflunine",
        "  Patients randomised in the test arm (arm A) received VFL at the dose of 280 mg/m\u00b2 on day 1 of each cycle every 3 weeks, over a 20-minute intravenous (IV) infusion. Cycles were repeated every 3 weeks.",
        "  vinflunine: 280 mg/m2 on day 1 of each cycle every 3 weeks",
        "INTERVENTION 2: ",
        "  Alkylating Agent",
        "  Patients randomised in the control arm (arm B) received an alkylating agent used as a single agent which was available in the investigational center and was approved for the treatment of cancer in the country.",
        "  Alkylating agent of physician choice registered in cancer: cyclophosphamide or melphalan or mitomycin C or thiotepa or cisplatin or carboplatin"
    ],
    "Eligibility": [
        "Inclusion Criteria:(main conditions)",
        "  Female patients 18 to 75 years of age with metastatic breast cancer histologically/cytologically confirmed not amenable to curative surgery or radiotherapy and who have received at least two prior chemotherapy regimens including anthracyclines,taxanes,antimetabolite and vinca-alkaloid and are no longer candidate for these drugs,",
        "  Karnofsky performance score of at least 70 %, adequate haematological, hepatic and renal functions and ECG without clinically relevant abnormality.",
        "Exclusion Criteria:",
        "  Concurrent serious uncontrolled medical disorder,",
        "  known or clinical evidence of brain metastases or leptomeningeal involvement,",
        "  pulmonary lymphangitis or symptomatic pleural effusion or symptomatic ascites,",
        "  history of second primary malignancy,",
        "  HIV infection, preexisting neuropathy,",
        "  pregnancy or breast feeding."
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Overall Survival",
        "  The main endpoint of this study is overall survival defined as the time from randomisation to the date of death or last follow-up. For patients who have not died, survival duration will be censored at the date of last contact or last follow-up or the date of last news.",
        "  Time frame: From baseline up to 3 years 1 month",
        "Results 1: ",
        "  Arm/Group Title: Vinflunine",
        "  Arm/Group Description: Patients randomised in the test arm (arm A) received VFL at the dose of 280 mg/m  on day 1 of each cycle every 3 weeks, over a 20-minute intravenous (IV) infusion. Cycles were repeated every 3 weeks.",
        "  vinflunine: 280 mg/m2 on day 1 of each cycle every 3 weeks",
        "  Overall Number of Participants Analyzed: 298",
        "  Median (95% Confidence Interval)",
        "  Unit of Measure: Months  9.1        (7.7 to 10.4)",
        "Results 2: ",
        "  Arm/Group Title: Alkylating Agent",
        "  Arm/Group Description: Patients randomised in the control arm (arm B) received an alkylating agent used as a single agent which was available in the investigational center and was approved for the treatment of cancer in the country.",
        "  Alkylating agent of physician choice registered in cancer: cyclophosphamide or melphalan or mitomycin C or thiotepa or cisplatin or carboplatin",
        "  Overall Number of Participants Analyzed: 296",
        "  Median (95% Confidence Interval)",
        "  Unit of Measure: Months  9.3        (7.5 to 10.9)"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 82/297 (27.61%)",
        "  Neutropenia 6/297 (2.02%)",
        "  Anaemia 6/297 (2.02%)",
        "  Febrile neutropenia 3/297 (1.01%)",
        "  Thrombocytopenia 1/297 (0.34%)",
        "  Endocardititis staphylococcal 1/297 (0.34%)",
        "  Arteriospasm coronary 1/297 (0.34%)",
        "  Atrial fibrillation 1/297 (0.34%)",
        "  Cardiac failure 0/297 (0.00%)",
        "  Constipation 5/297 (1.68%)",
        "  Vomiting 6/297 (2.02%)",
        "  Abdominal pain 4/297 (1.35%)",
        "Adverse Events 2:",
        "  Total: 66/290 (22.76%)",
        "  Neutropenia 0/290 (0.00%)",
        "  Anaemia 0/290 (0.00%)",
        "  Febrile neutropenia 1/290 (0.34%)",
        "  Thrombocytopenia 2/290 (0.69%)",
        "  Endocardititis staphylococcal 0/290 (0.00%)",
        "  Arteriospasm coronary 0/290 (0.00%)",
        "  Atrial fibrillation 1/290 (0.34%)",
        "  Cardiac failure 1/290 (0.34%)",
        "  Constipation 0/290 (0.00%)",
        "  Vomiting 3/290 (1.03%)",
        "  Abdominal pain 1/290 (0.34%)"
    ]
}